Medicare Coverage for Heart Disease: 2025 Guide
Heart disease is the leading cause of death in the United States — and Medicare is the primary insurer for most people diagnosed after 65. From cardiac rehabilitation to stent placements, remote monitoring, and a landmark 2024 coverage expansion for Wegovy, here's what Medicare covers and what still has gaps.
Heart Disease Coverage at a Glance
| Service | Part | Your Cost (2025) | Notes |
|---|---|---|---|
| Cardiac rehabilitation (standard) | Part B | 20% after $257 deductible | 36 sessions/benefit period; up to 72 if medically necessary |
| Intensive Cardiac Rehabilitation (ICR) | Part B | 20% after deductible | Up to 72 sessions; intensive programs like Ornish, MULTIFIT |
| Heart attack (MI) hospitalization | Part A | $1,676 deductible per benefit period | Days 1–60: $0 coinsurance after deductible |
| Bypass surgery (CABG) | Part A (inpatient) | Part A deductible | Also covered outpatient under Part B if ambulatory |
| Coronary angioplasty / stent | Part B or A | 20% (Part B) or deductible (Part A) | Setting determines which part covers |
| Heart valve repair/replacement | Part A (inpatient) | Part A deductible | TAVR (transcatheter) covered when criteria met |
| Pacemaker / ICD implantation | Part A or B | Deductible or 20% | Note: pacemaker/ICD does NOT qualify for cardiac rehab |
| EKG / echocardiogram | Part B | 20% after deductible | Covered when medically necessary |
| Stress test / nuclear stress test | Part B | 20% after deductible | Exercise or pharmacologic stress testing |
| Coronary angiogram / cardiac cath | Part B (outpatient) or A (inpatient) | 20% or deductible | Diagnostic catheterization covered |
| Cardiovascular disease screening | Part B (preventive) | $0 — free | Lipid panel once per 5 years; no age requirement |
| Remote cardiac monitoring (RPM) | Part B | 20% after deductible | Expanded coverage; requires physician supervision |
| Holter monitor / event monitor | Part B (DME) | 20% after deductible | 30-day event monitors and wearable monitors covered |
| Heart failure cardiac rehab | Part B | 20% after deductible | Stable CHF with EF ≤35%; NYHA Class II–IV |
| Statins, beta-blockers, ACE inhibitors | Part D | Usually Tier 1–2 (low cost) | Generic versions very affordable under Part D |
| Wegovy (semaglutide) for CV risk | Part D | Varies; $2,000 annual cap applies | Requires established CVD + BMI ≥27; new 2024 coverage |
Cardiac Rehabilitation: Who Qualifies
Medicare Part B covers cardiac rehabilitation programs for patients who have experienced one of the following qualifying events:
- Heart attack (myocardial infarction) within the past 12 months
- Coronary artery bypass surgery (CABG)
- Stable angina pectoris
- Heart valve repair or replacement
- Coronary angioplasty or coronary stenting
- Heart or heart-lung transplant
- Stable, chronic heart failure (expanded coverage): EF ≤35%, NYHA Class II–IV
Standard cardiac rehab covers up to 36 sessions per benefit period (up to 2 sessions per day), extendable to 72 sessions with medical documentation. Intensive Cardiac Rehabilitation (ICR) programs like Dean Ornish are covered for up to 72 sessions. Both are covered at 20% coinsurance after the Part B deductible.
Remote Patient Monitoring for Heart Conditions
Medicare has significantly expanded coverage for remote patient monitoring (RPM) — technology that allows physicians to track cardiac data from a patient's home. Covered RPM services include:
- Continuous cardiac monitoring devices (wearable ECG patches, implantable loop recorders)
- Blood pressure monitoring with data transmission
- Weight monitoring for heart failure patients
- Pulse oximetry monitoring
RPM for heart failure patients in particular has been shown to reduce hospitalizations. Medicare covers the device, data transmission, and monthly review by a physician. This benefit is underutilized because many patients and providers are unaware of its availability.
Wegovy for Cardiovascular Risk: The 2024 Coverage Expansion
In March 2024, the FDA approved Wegovy (high-dose semaglutide) for a new indication: reducing the risk of serious cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease who are overweight or obese.
Medicare Part D now covers Wegovy under this cardiovascular indication — the first time Medicare covers a GLP-1 drug for non-diabetes purposes. To qualify:
- Must have established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease)
- Must have a BMI ≥27 (overweight or obese)
- Coverage is under Part D (subject to formulary and the $2,000 annual out-of-pocket cap)
Note: Wegovy prescribed purely for weight loss without a cardiovascular disease diagnosis is still not covered by Medicare under federal law.
What Medicare Does NOT Cover for Heart Disease
- Transportation to cardiac rehab: Rides to and from rehab sessions are not covered under Original Medicare (some MA plans offer transportation benefits)
- Experimental cardiac devices: Devices not yet FDA-approved may not be covered outside of approved clinical trials
- Home health aide (custodial) care: Non-medical personal care assistance at home is not covered
- Cardiac diet programs: Commercial weight management programs (except specific Medicare-covered behavioral counseling sessions) are not covered
- Some wearable consumer devices: Consumer smartwatches with cardiac monitoring features are not covered as DME
Heart Disease and Medigap: Why Coverage Matters
Heart disease often requires ongoing specialist care, frequent diagnostic tests, and potential procedures — all generating Part B coinsurance. Without Medigap, these 20% costs accumulate quickly:
- A coronary stent procedure billed at $15,000 → $3,000 out of pocket (20%)
- 36 cardiac rehab sessions at $300 each → $2,160 in coinsurance
- Monthly cardiologist visits at $200 → $480/year in 20% coinsurance
Medigap Plan G covers all Part B coinsurance after the $257 annual deductible, making all of the above essentially free. For anyone with established heart disease or significant cardiac risk factors, Plan G typically provides substantial financial value.
Frequently Asked Questions
Yes. Coronary artery bypass surgery (CABG) and heart valve surgery are covered under Medicare Part A as inpatient procedures. You pay the Part A deductible ($1,676 per benefit period in 2025). Days 1–60 have no additional coinsurance after the deductible. Medigap Plan G covers the Part A deductible as well.
Yes, for qualifying conditions (heart attack, bypass, stent, valve surgery, stable angina, heart transplant, and stable CHF). Medicare Part B covers up to 36 sessions per benefit period, extendable to 72 with medical necessity. You pay 20% coinsurance after the Part B deductible. Medigap Plan G covers that 20%.
Yes, with conditions. Medicare covers TAVR for patients with severe aortic stenosis who meet specific clinical criteria. Coverage requires that the procedure be performed at a facility that meets CMS volume and quality requirements, and that a multidisciplinary heart team evaluates the patient. Coverage was significantly expanded in 2019 to include lower-risk patients.
Yes. Common heart medications — statins (atorvastatin, rosuvastatin), beta-blockers (metoprolol, carvedilol), ACE inhibitors (lisinopril, ramipril), ARBs, anticoagulants (warfarin, newer anticoagulants like Eliquis) — are all covered by Part D. Generic versions of most heart medications are very affordable, often $0–$10/month on Tier 1. Brand-name anticoagulants like Eliquis are more expensive but subject to the $2,000 annual cap since 2025.